This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Eisai Co., Ltd.
Drug Names(s): E6201, E-6201
Description: E6201 is a multi-kinase inhibitor. It acts to inhibits lipopolysaccharide-activated TNF-alpha, and selectively inhibits mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK)-1 and MEK kinase-1 in cell-free biochemical assays. Based upon in vitro data E6201 may be beneficial for treatment of inflammatory and hyperproliferative diseases such as psoriasis through its anti-inflammatory activities on immune cells and antihyperproliferative activities on keratinocytes.
Eisai and Quintiles
In October 2009, Eisai entered into a strategic alliance with Eisai to develop six potential oncology products in Eisais R&D pipeline. Under the terms of the agreement, Quintiles oncology experts will conduct Phase II proof-of-concept studies for 11 solid tumor indications. The strategic alliance will be structured on a risk-sharing basis, with Quintiles funding, in part, the design and conduct of the clinical studies in exchange for success milestone payments. Other financial terms were not disclosed. The agreement is designed to enable Eisai to extend its oncology program, increasing the number of indications investigated for the six potential products, including eribulin (E7389), E7080, Ontak (denileukin diftitox), E7820, E6201 and E7050. These assets will remain the property of Eisai, with Quintiles having development accountability through the Phase II proof-of-concept stage. Quintiles will collaborate on Phase Ib/II studies of E6201 in breast...See full deal structure in Biomedtracker
Partners: Quintiles Transnational Holdings, Inc. Strategia Therapeutics, Inc.
Scrip Antibodies Evolve
Additional information available to subscribers only: